FX-322 in Adults With Age-Related Sensorineural Hearing Loss

Sponsor

Frequency Therapeutics (Industry)

Overall Status

Completed

CT.gov ID

NCT04601909

Collaborator

(none)

Enrollment

Locations

Arms

19.9

Actual Duration (Months)

Patients Per Site

0.3

Patients Per Site Per Month

Study Details

Study Description

Brief Summary

This is a Phase 1b, prospective, randomized, double-blind, placebo-controlled, single-dose, multicenter, safety study of FX-322, administered by intratympanic injection, in adults with age-related sensorineural hearing loss.

Condition or Disease	Intervention/Treatment	Phase
Presbycusis Hearing Loss, Sensorineural Noise Induced Hearing Loss Sudden Hearing Loss	Drug: FX-322 Other: placebo	Phase 1

Detailed Description

This is a Phase 1b placebo-controlled, double-blind, randomized, single-dose safety study of intratympanic FX-322 dosed in subjects with age-related sensorineural hearing loss.

Approximately 30 subjects are planned to be enrolled in this study. The subjects will be randomized to receive one dose FX-322 (24) or placebo (6) and will return for safety, otologic, and audiologic assessments at Days 30 and 90 after the study injection.

Study Design

Study Type:

Interventional

Actual Enrollment :

30 participants

Allocation:

Randomized

Intervention Model:

Parallel Assignment

Intervention Model Description:

Approximately 30 subjects are planned to be enrolled in this study. The subjects will be randomized to receive FX-322 or placebo randomized 4:1.Approximately 30 subjects are planned to be enrolled in this study. The subjects will be randomized to receive FX-322 or placebo randomized 4:1.

Masking:

Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)

Masking Description:

Double-blind

Primary Purpose:

Treatment

Official Title:

A Phase 1b, Prospective, Randomized, Double-Blind, Placebo-Controlled, Single-Dose, Multicenter, Safety Study of FX-322 Administered by Intratympanic Injection in Adults With Age-Related Sensorineural Hearing Loss

Actual Study Start Date :

Sep 17, 2020

Actual Primary Completion Date :

May 16, 2022

Actual Study Completion Date :

May 16, 2022

Arms and Interventions

Arm	Intervention/Treatment
Active Comparator: FX-322 FX-322, 1 dose (N=24)	Drug: FX-322 active comparator
Placebo Comparator: Placebo Placebo, 1 dose (n=6)	Other: placebo placebo

Arm

Intervention/Treatment

Active Comparator: FX-322

FX-322, 1 dose (N=24)

Drug: FX-322

active comparator

Placebo Comparator: Placebo

Placebo, 1 dose (n=6)

Other: placebo

placebo

Outcome Measures

Primary Outcome Measures

Systemic Safety: Number of patients with treatment-related adverse events [3 months]
Number of patients with treatment-related adverse events assessed by CTCAE v5.0
Local Safety: Number of patients with abnormal changes from baseline in otoscopic examinations [3 months]
Microscopic otoscopy will be included to specifically record any abnormalities of the external ear canal, tympanic membrane and middle ear.
Local Safety: The number of patients with abnormal changes from baseline in tympanometry [3 months]
Tympanometry tests the integrity of the tympanic membrane by varying air pressure in the ear canal. Middle ear compliance (mL), peak pressure (daPa), and ear canal volume (mL) will be recorded.
Columbia-Suicide Severity Rating Scale (C-SSRS) [3 months]
Risk assessment through a series of simple, plain-language questions

Secondary Outcome Measures

Audiologic Response Endpoints: Speech Intelligibility - Word Recognition in Quiet (WR) [3 months]
Assessment of speech intelligibility using the Word Recognition in Quiet test measured with Consonant-Nucleus-Consonant (CNC) word lists.
Audiologic Response Endpoints: Speech Intelligibility - Words-In-Noise (WIN) [3 months]
Speech intelligibility using the Words-in-Noise test measured with Consonant-Nucleus-Consonant (CNC) word lists
Standard Pure Tone Audiometry [3 months]
Standard pure tone audiometry will be measured to determine a subject's threshold for hearing at standard frequencies (Hz)
Extended High Frequency Pure Tone Audiometry [3 months]
Pure tone audiometry will be measured to determine a subject's threshold for hearing at extended high range frequencies (Hz)
Tinnitus Assessment [3 months]
Measured by the Tinnitus Functional Index (TFI), with a scale ranging from 0 to 100 that defines severity categories based on 25 self-reported answers.

Eligibility Criteria

Criteria

Ages Eligible for Study:

66 Years to 85 Years

Sexes Eligible for Study:

All

Accepts Healthy Volunteers:

Inclusion Criteria:

Subject has read and voluntarily signed the Informed Consent Form (ICF) after all questions have been answered and prior to any study-mandated procedure.
Adult aged 66-85 years inclusive.
Documented medical history consistent with age-related sensorineural hearing loss (documented audiogram at least 6 months prior to screening required).
A pure tone average of 26-70 dB at 500Hz, 1000Hz, 2000Hz, and 4000Hz at Screening in the ear to be injected.
Ability to communicate well with the Investigator and is willing to comply with and complete all the study procedures.

Exclusion Criteria:

Subject has previously participated in a FX-322 clinical trial.
Any subject with a flat audiogram between 500Hz and 8000Hz at Screening in the study ear. The difference in the range of threshold values across frequencies is ≤15 dB for the definition of a flat audiogram.
Clinically significant abnormalities on safety laboratory tests.
Perforation of tympanic membrane or other tympanic membrane disorders that would interfere with the delivery and safety assessment of an intratympanic medication or reasonably be suspected to affect tympanic membrane healing after injection in study ear. This includes a current tympanostomy tube.
Any conductive hearing loss of greater than 15 dB at a single frequency or greater than 10 dB at two or more contiguous octave frequencies in the study ear at the Screening visit or on the prior audiogram (if the Investigator feels there is not a true conductive hearing loss, the Medical Monitor should be consulted).
Active chronic middle ear disease or a history of major middle ear surgery, as an adult, in the ear to be injected.
Subject has had an intratympanic injection in either ear within 3 months of the screening visit.
History of clinically significant vestibular symptoms at the discretion of the investigator. For example, BPPV may be considered acceptable whereas Meniere's would not.
History of clinically significant systemic autoimmune disease (e.g. rheumatoid arthritis, Sjogren's syndrome, multiple sclerosis, psoriasis).
Exposure to another investigational drug within 28 days prior to injection of study drug.
Evidence of any active or chronic disease or condition that could interfere with, or for which the treatment of might interfere with, the conduct of the study, or that would pose an unacceptable risk to the subject in the opinion of the investigator following a detailed medical history, physical examination, and vital signs (systolic and diastolic blood pressure, pulse rate, body temperature).
Females of childbearing potential (those who are not surgically sterilized or post-menopausal) may not participate in the study if any of the following conditions exist:

Pregnant or intend to become pregnant
Nursing (lactating)
Does not agree to use adequate birth control methods for the duration of the study (adequate birth control methods are: hormonal- oral, implantable, transdermal or injectable contraceptives; mechanical- spermicide in conjunction with a barrier such as a condom or diaphragm, IUD, or surgical sterilization of a partner.

NOTE: all female subjects of childbearing potential must consent to a urine pregnancy test as described in the Schedule of Assessments

Any known factor, condition, or disease that, in the view of the Investigator, might interfere with treatment compliance, study conduct or interpretation of the results (e.g. previous high-dose aminoglycoside treatment).

Contacts and Locations

Locations

	Site	City	State	Country
1	Clinical Trial Site	Sarasota	Florida	United States
2	Clinical Trial Site	Omaha	Nebraska	United States
3	Clinical Trial Site	Amherst	New York	United States
4	Clinical Trial Site	San Antonio	Texas	United States
5	Clinical Trial Site	Norfolk	Virginia	United States